Literature DB >> 7682782

Functional difference between SP and NKA: relaxation of gastric muscle by SP is mediated by VIP and NO.

J G Jin1, S Misra, J R Grider, G M Makhlouf.   

Abstract

The mechanism of action of endogenous tachykinins [substance P (SP) and neurokinin A and B (NKA and NKB)] and of receptor-specific tachykinin analogues (SP methyl ester (SPME), [beta-Ala8]NKA-(4-10), and senktide) was examined in circular muscle of guinea pig stomach. Cross-desensitization studies confirmed that SPME and SP interacted with NK-1 receptors, [beta-Ala8]NKA-(4-10) and NKA with NK-2 receptors, and senktide and NKB with NK-3 receptors. NK-1 and NK-3-receptor agonists induced relaxation and stimulated vasoactive intestinal peptide (VIP) release and nitric oxide (NO) production: tetrodotoxin abolished VIP release, NO production, and relaxation, converting the response to NK-1-receptor agonists to contraction; the NO synthase inhibitor NG-nitro-L-arginine (L-NNA) abolished NO production, partly inhibited VIP release (56-64%, P < 0.01), and abolished relaxation; the VIP antagonist VIP-(10-28) partly inhibited NO production (73-74%, P < 0.001) and relaxation (56-58%, P < 0.01); and atropine augmented relaxation by 28-35% (P < 0.01). The pattern of inhibition implied that: 1) relaxation was mediated by VIP and NO; 2) VIP release was partly dependent on NO production, since it was strongly inhibited by L-NNA; and 3) NO was largely produced by the action of VIP on muscle cells, since it was strongly inhibited by VIP-(10-28). NK-2-receptor agonists elicited only contraction that was not affected by tetrodotoxin; these agonists also inhibited VIP release, NO production, and relaxation induced by NK-1- and NK-3-receptor agonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682782     DOI: 10.1152/ajpgi.1993.264.4.G678

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Local cardiac effects of substance P: roles of acetylcholine and noradrenaline.

Authors:  H Chiao; R W Caldwell
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

2.  The role of substance P in myocardial dysfunction during ischemia and reperfusion.

Authors:  H Chiao; R W Caldwell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

3.  Modulation by nitric oxide of spontaneous motility of the rat isolated duodenum: role of tachykinins.

Authors:  M A Martinez-Cuesta; J V Esplugues; B J Whittle
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  Nitric oxide synthase (NOS) expression in the myenteric plexus of streptozotocin-diabetic rats.

Authors:  H F Wrzos; A Cruz; R Polavarapu; D Shearer; A Ouyang
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

5.  The ineffectiveness of the NO-cyclic GMP signaling pathway in the atrial myocardium.

Authors:  H Nawrath; D Bäumner; J Rupp; H Oelert
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 6.  Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Authors:  Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

7.  In vivo evidence for the involvement of tachykinin NK3 receptors in the hexamethonium-resistant inhibitory transmission in the rat colon.

Authors:  A Lecci; S Giuliani; M Tramontana; S Meini; R De Giorgio; C A Maggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-05       Impact factor: 3.000

8.  Role of NK1 and NK2 receptors in mouse gastric mechanical activity.

Authors:  Flavia Mulè; Antonella Amato; Maria Giuliana Vannucchi; Maria Simonetta Faussone-Pellegrini; Rosa Serio
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

9.  The effect of Xenin25 on spontaneous circular muscle contractions of rat distal colon in vitro.

Authors:  Yuko Kuwahara; Ikuo Kato; Toshio Inui; Yoshinori Marunaka; Atsukazu Kuwahara
Journal:  Physiol Rep       Date:  2021-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.